期刊文献+

pT1N1M0胃癌患者辅助化疗适宜人群的研究 被引量:1

A study on candidates benefiting from adjuvant chemotherapy in patients with pT1N1M0 gastric cancer
原文传递
导出
摘要 目的探讨辅助化疗是否对所有pT1N1M0(ⅠB期)的胃癌患者有生存获益。方法回顾性分析2010年1月至2016年12月在河南省肿瘤医院经手术切除并经病理学证实的185例pT1N1M0胃癌患者的临床资料,根据是否进行辅助化疗分为化疗组(n=100)和非化疗组(n=85)。结果单因素生存分析显示:年龄、送检淋巴结数目、脉管侵犯、神经侵犯及辅助化疗均与胃癌患者的无病生存有关(均P<0.05);多因素生存分析显示:送检淋巴结数目≥16枚(HR=0.363,95%CI:0.160~0.827,P=0.016)、脉管侵犯(HR=4.117,95%CI:1.796~9.436,P=0.001)及辅助化疗(HR=4.530,95%CI:1.932~10.622,P=0.001)均是影响胃癌患者无病生存的独立危险因素。单因素生存分析显示:送检淋巴结数目、脉管侵犯、神经侵犯及辅助化疗均与胃癌患者的疾病特异性生存有关(均P<0.05);多因素生存分析显示:送检淋巴结数目≥16枚(HR=0.344,95%CI:0.144~0.822,P=0.016)、脉管侵犯(HR=5.113,95%CI:2.029~12.887,P=0.001)和辅助化疗(HR=4.694,95%CI:1.854~11.888,P=0.001)均是影响胃癌患者疾病特异性生存的独立危险因素。根据两个重要的预后因素(送检淋巴结数目和脉管侵犯)将pT1N1M0患者分为高、中、低3个风险类别,发现3个风险组之间的无病生存和疾病特异性生存差异均有统计学意义(均P<0.001)。结论诊断为pT1N1M0的胃癌患者有望从辅助化疗中生存获益;淋巴结送检数目不足16枚和脉管侵犯的患者可能特别适合辅助化疗。 Objective To investigate whether adjuvant chemotherapy could be beneficial for patients with pT1N1M0(stageⅠB)gastric cancer.Methods From Jan 2010 to Dec 2016,185 patients with pT1N1M0 gastric cancer who were surgically resected at Henan Cancer Hospital were retrospectively analyzed.The patients were divided into chemotherapy group(n=100)and non chemotherapy group(n=85).Results For disease-free survival(DFS)analysis,univariate survival analysis showed that age,examined lymph nodes,vascular invasion,nerve invasion and adjuvant chemotherapy were associated with DFS(all P<0.05);multivariate analysis showed that lymph node resection≥16(HR=0.363,95%CI:0.160-0.827,P=0.016),vascular invasion(HR=4.117,95%CI:1.796-9.436,P=0.001)and postoperative chemotherapy(HR=4.530,95%CI:1.932-10.622,P=0.001)were independent risk factors for DFS.For disease-specific survival(DSS)analysis,univariate survival analysis showed that lymph node resection,vascular invasion,nerve invasion and adjuvant chemotherapy were associated with DSS;multivariate analysis showed that lymph node resection≥16(HR=0.344,95%CI:0.144-0.822,P=0.016),vascular invasion(HR=5.113,95%CI:2.029-12.887,P=0.001)and postoperative chemotherapy(HR=4.694,95%CI:1.854-11.888,P=0.001)were independent risk factors for DSS.According to examined lymph nodes and vascular invasion,pT1N1M0 patients were divided into three risk categories(high,medium and low).DFS and DSS were significantly different among the three risk groups(all P<0.001,respectively).Conclusion pT1N1M0 gastric cancer patients are expected to benefit from adjuvant chemotherapy.Patients with less than 16 lymph nodes and vascular invasion may be particularly suitable for adjuvant chemotherapy.
作者 李森 马鹏飞 张俊立 曹养辉 刘晨宇 张习杰 薛英威 赵玉洲 Li Sen;Ma Pengfei;Zhang Junli;Cao Yanghui;Liu Chenyu;Zhang Xijie;Xue Yingwei;Zhao Yuzhou(Department of General Surgery,the Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450008,China;Department of Gastroenterological Surgery,Harbin Medical University Cancer Hospital,Harbin 150081,China)
出处 《中华普通外科杂志》 CSCD 北大核心 2021年第4期254-258,共5页 Chinese Journal of General Surgery
基金 河南省高等学校重点科研项目 (20A320016)。
关键词 胃肿瘤 肿瘤辅助治疗 预后 肿瘤分期 Stomach neoplsms Neoadjuvant therapy Prognosis Neoplasm staging
  • 引文网络
  • 相关文献

参考文献2

二级参考文献15

  • 1Wasaburo Koizumi,Hiroyuki Narahara,Takuo Hara,Akinori Takagane,Toshikazu Akiya,Masakazu Takagi,Kosei Miyashita,Takashi Nishizaki,Osamu Kobayashi,Wataru Takiyama,Yasushi Toh,Takashi Nagaie,Seiichi Takagi,Yoshitaka Yamamura,Kimihiko Yanaoka,Hiroyuki Orita,Masahiro Takeuchi.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial[J]. Lancet Oncology . 2008 (3)
  • 2Hye SeongAhn,Hyuk‐JoonLee,SeokyungHahn,Woo‐HoKim,Kuhn UkLee,TakeshiSano,Stephen BEdge,Han‐KwangYang.Evaluation of the Seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification[J].Cancer.2010(24)
  • 3Narikazu Boku,Seiichiro Yamamoto,Haruhiko Fukuda,Kuniaki Shirao,Toshihiko Doi,Akira Sawaki,Wasaburo Koizumi,Hiroshi Saito,Kensei Yamaguchi,Hiroya Takiuchi,Junichiro Nasu,Atsushi Ohtsu.Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study[J].Lancet Oncology.2009(11)
  • 4Toru Aoyama,Takaki Yoshikawa,Tsutomu Hayashi,Hiroshi Kuwabara,Yo Mikayama,Takashi Ogata,Haruhiko Cho,Akira Tsuburaya.Risk Factors for Peritoneal Recurrence in Stage II/III Gastric Cancer Patients Who Received S-1 Adjuvant Chemotherapy After D2 Gastrectomy[J].Annals of Surgical Oncology.2012(5)
  • 5Takanobu Yamada,Tsutomu Hayashi,Haruhiko Cho,Takaki Yoshikawa,Hideki Taniguchi,Ryoji Fukushima,Akira Tsuburaya.Usefulness of enhanced recovery after surgery protocol as compared with conventional perioperative care in gastric surgery[J].Gastric Cancer.2012(1)
  • 6Takashi Yokoyama,Kiyoshi Kamada,Yoshikazu Tsurui,Hisanori Kashizuka,Eiji Okano,Sanehito Ogawa,Shinsaku Obara,Mitsutoshi Tatsumi.Clinicopathological analysis for recurrence of stage Ib gastric cancer (according to the second English edition of the Japanese classification of gastric carcinoma)[J].Gastric Cancer.2011(4)
  • 7Toru Aoyama,Takaki Yoshikawa,Takafumi Watanabe,Tsutomu Hayashi,Takashi Ogata,Haruhiko Cho,Akira Tsuburaya.Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1[J].Gastric Cancer.2011(3)
  • 8Makoto Saka,Hitoshi Katai,Takeo Fukagawa,Rajwinder Nijjar,Takeshi Sano.Recurrence in early gastric cancer with lymph node metastasis[J].Gastric Cancer.2008(4)
  • 9Pompiliu Piso MD,Uwe Werner MD,Hauke Lang MD,Petrit Mirena MD,Jürgen Klempnauer MD.Proximal Versus Distal Gastric Carcinoma—What Are the Differences?[J].Annals of Surgical Oncology.2000(7)
  • 10武治铭,武爱文,李子禹,吴齐,张连海,吴晓江,宗祥龙,季加孚,步召德.157例早期胃癌淋巴结转移特点及预后分析[J].中华胃肠外科杂志,2009,12(4):350-353. 被引量:14

共引文献18

同被引文献3

引证文献1

;
使用帮助 返回顶部